Malignant  ||| S:0 E:10 ||| JJ
stroke  ||| S:10 E:17 ||| NN
in  ||| S:17 E:20 ||| IN
an  ||| S:20 E:23 ||| DT
adolescent  ||| S:23 E:34 ||| NN
with  ||| S:34 E:39 ||| IN
a  ||| S:39 E:41 ||| DT
homozygous  ||| S:41 E:52 ||| JJ
MTHFR  ||| S:52 E:58 ||| NNP
677CT  ||| S:58 E:64 ||| NNP
mutation  ||| S:64 E:73 ||| NN
and  ||| S:73 E:77 ||| CC
intake  ||| S:77 E:84 ||| NN
of  ||| S:84 E:87 ||| IN
hormonal  ||| S:87 E:96 ||| JJ
contraceptives  ||| S:96 E:111 ||| NNS
Severe  ||| S:111 E:118 ||| JJ
stroke  ||| S:118 E:125 ||| NN
in  ||| S:125 E:128 ||| IN
children  ||| S:128 E:137 ||| NNS
and  ||| S:137 E:141 ||| CC
adolescents  ||| S:141 E:153 ||| NNS
with  ||| S:153 E:158 ||| IN
its  ||| S:158 E:162 ||| PRP$
devastating  ||| S:162 E:174 ||| JJ
long  ||| S:174 E:179 ||| JJ
term  ||| S:179 E:184 ||| NN
consequences  ||| S:184 E:197 ||| NNS
remains  ||| S:197 E:205 ||| VBZ
a  ||| S:205 E:207 ||| DT
rare  ||| S:207 E:212 ||| JJ
disorder  ||| S:212 E:221 ||| NN
with  ||| S:221 E:226 ||| IN
many  ||| S:226 E:231 ||| JJ
open  ||| S:231 E:236 ||| JJ
questions ||| S:236 E:245 ||| NNS
.  ||| S:245 E:247 ||| .
Beside  ||| S:247 E:254 ||| IN
the  ||| S:254 E:258 ||| DT
well  ||| S:258 E:263 ||| RB
known  ||| S:263 E:269 ||| VBN
risk  ||| S:269 E:274 ||| NN
factors  ||| S:274 E:282 ||| NNS
such  ||| S:282 E:287 ||| JJ
as  ||| S:287 E:290 ||| IN
infection  ||| S:290 E:300 ||| NN
or  ||| S:300 E:303 ||| CC
congenital  ||| S:303 E:314 ||| NNS
and  ||| S:314 E:318 ||| CC
acquired  ||| S:318 E:327 ||| VBN
heart  ||| S:327 E:333 ||| NN
disease ||| S:333 E:340 ||| NN
,  ||| S:340 E:342 ||| ,
coagulation  ||| S:342 E:354 ||| JJ
disorders  ||| S:354 E:364 ||| NNS
have  ||| S:364 E:369 ||| VBP
to  ||| S:369 E:372 ||| TO
be  ||| S:372 E:375 ||| VB
considered  ||| S:375 E:386 ||| VBN
in  ||| S:386 E:389 ||| IN
the  ||| S:389 E:393 ||| DT
differential  ||| S:393 E:406 ||| JJ
work  ||| S:406 E:411 ||| NN
up  ||| S:411 E:414 ||| RP
of  ||| S:414 E:417 ||| IN
the  ||| S:417 E:421 ||| DT
underlying  ||| S:421 E:432 ||| JJ
aetiology ||| S:432 E:441 ||| NN
.  ||| S:441 E:443 ||| .
Here  ||| S:443 E:448 ||| RB
we  ||| S:448 E:451 ||| PRP
report  ||| S:451 E:458 ||| VBP
the  ||| S:458 E:462 ||| DT
case  ||| S:462 E:467 ||| NN
of  ||| S:467 E:470 ||| IN
an  ||| S:470 E:473 ||| DT
adolescent  ||| S:473 E:484 ||| NN
with  ||| S:484 E:489 ||| IN
a  ||| S:489 E:491 ||| DT
homozygote  ||| S:491 E:502 ||| JJ
MTHFR  ||| S:502 E:508 ||| NNP
677CT  ||| S:508 E:514 ||| NNP
mutation  ||| S:514 E:523 ||| VBZ
suffering  ||| S:523 E:533 ||| VBG
a  ||| S:533 E:535 ||| DT
malignant  ||| S:535 E:545 ||| JJ
stroke  ||| S:545 E:552 ||| NN
shortly  ||| S:552 E:560 ||| RB
after  ||| S:560 E:566 ||| IN
the  ||| S:566 E:570 ||| DT
start  ||| S:570 E:576 ||| NN
of  ||| S:576 E:579 ||| IN
oral  ||| S:579 E:584 ||| JJ
contraceptives ||| S:584 E:598 ||| NNS
.  ||| S:598 E:600 ||| .
Since  ||| S:600 E:606 ||| IN
prevention  ||| S:606 E:617 ||| NN
seems  ||| S:617 E:623 ||| VBZ
easily  ||| S:623 E:630 ||| RB
feasible ||| S:630 E:638 ||| JJ
,  ||| S:638 E:640 ||| ,
general  ||| S:640 E:648 ||| JJ
screening  ||| S:648 E:658 ||| NN
for  ||| S:658 E:662 ||| IN
MTHFR  ||| S:662 E:668 ||| NNP
mutations  ||| S:668 E:678 ||| NNS
might  ||| S:678 E:684 ||| MD
be  ||| S:684 E:687 ||| VB
worthwhile  ||| S:687 E:698 ||| JJ
in  ||| S:698 E:701 ||| IN
women  ||| S:701 E:707 ||| NNS
before  ||| S:707 E:714 ||| IN
starting  ||| S:714 E:723 ||| VBG
oral  ||| S:723 E:728 ||| JJ
contraceptives ||| S:728 E:742 ||| NNS
.  ||| S:742 E:744 ||| .
